Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Fluoride Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132957 | 0.95 | — | — | |
| Potassium Fluoride SCHEMBL27832151 | 0.90 | DGAT1 (0.36) | DGAT1ALDH1A1KCNN4L3MBTL1MAPT | |
| SCHEMBL30957003 | 0.80 | PKM (0.40) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL9806073 | 0.78 | DGAT1 (0.39) | DGAT1ALDH1A1KCNN4L3MBTL1MAPT | |
| SCHEMBL3592898 | 0.78 | — | — | |
| SCHEMBL23869987 | 0.76 | — | — | |
| SCHEMBL1240770 | 0.74 | DGAT1 (0.36) | DGAT1ALDH1A1KCNN4L3MBTL1MAPT | |
| SCHEMBL28776282 | 0.74 | ALDH1A1 (0.39) | DGAT1ALDH1A1KCNN4L3MBTL1MAPT | |
| SCHEMBL18398859 | 0.73 | — | — | |
| SCHEMBL8165907 | 0.72 | DGAT1 (0.39) | DGAT1ALDH1A1KCNN4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3856178-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-08-04 | — | — | EP | disclosed |
| CN-113164459-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020065613-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7960392-B2 | Nitrogen-containing heterocyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2314587-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100029690-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | DGAT1 45/4885ALDH1A1 312/4885KCNN4 4210/4885 |
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | DGAT1 1778/4885ALDH1A1 286/4885KCNN4 2198/4885 |
| US-20200102303-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | DGAT1 45/4885ALDH1A1 312/4885KCNN4 4210/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | DGAT1 45/4885ALDH1A1 312/4885KCNN4 4210/4885 |
| US-20100029690-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | PTGER1, PTGS1, PTGER2 | DGAT1 3701/4885ALDH1A1 164/4885KCNN4 1311/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | DGAT1 45/4885ALDH1A1 312/4885KCNN4 4210/4885 |
| US-20100160256-A1 | INDAZOLE COMPOUNDS | GPR119, ADRB1, ADRA1A | DGAT1 955/4885ALDH1A1 131/4885KCNN4 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.